CORC

在结果中检索

CORC

浏览/检索结果: 共33条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic EGFR mutation from a phase I 期刊论文
BMC MEDICINE, 2023, 卷号: 21, 期号: 1
作者:  Yuankai Shi;  Jianying Zhou;  Yanqiu Zhao;  Bo Zhu;  Liangming Zhang
收藏  |  浏览/下载：0/0  |  提交时间：2024/05/07
HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib 期刊论文
ANNALS OF PALLIATIVE MEDICINE, 2022, 卷号: 11
作者:  Fan, Ying;  Qin, Jing;  Han, Na;  Lu, Hongyang
收藏  |  浏览/下载：17/0  |  提交时间：2022/12/23
LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo 期刊论文
CANCER SCIENCE, 2021, 页码: 12
作者:  Liu, Yingqiang;  Lai, Mengzhen;  Li, Shan;  Wang, Yanan;  Feng, Fang
收藏  |  浏览/下载：62/0  |  提交时间：2022/01/18
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance (vol 19, 90, 2020) 期刊论文
MOLECULAR CANCER, 2021, 卷号: 20, 期号: 1, 页码: 1
作者:  Zhang, Tao;  Qu, Rong;  Chan, Shingpan;  Lai, Mengzhen;  Tong, Linjiang
收藏  |  浏览/下载：58/0  |  提交时间：2021/11/04
Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance 期刊论文
Molecular Cancer, 2021, 卷号: 20, 期号: 1
作者:  Zhang,Tao;  Qu,Rong;  Chan,Shingpan;  Lai,Mengzhen;  Tong,Linjiang
收藏  |  浏览/下载：41/0  |  提交时间：2021/11/04
Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers 期刊论文
ACTA PHARMACOLOGICA SINICA, 2021, 页码: 9
作者:  Liu, Lu;  Li, Wei;  Yang, Le;  Guo, Zi-tao;  Xue, Hao
收藏  |  浏览/下载：78/0  |  提交时间：2021/08/17
Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells 期刊论文
THORACIC CANCER, 2021, 页码: 9
作者:  Zhang, Mi;  Quan, Haitian;  Fu, Li;  Li, Yun;  Fu, Haoyu
收藏  |  浏览/下载：19/0  |  提交时间：2021/05/24
Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers 期刊论文
INVESTIGATIONAL NEW DRUGS, 2021, 页码: 8
作者:  Zhu, Yun-ting;  Zhang, Yi-fan;  Jiang, Jin-fang;  Yang, Yong;  Guo, Li-xia
收藏  |  浏览/下载：27/0  |  提交时间：2021/05/24
Safety, Clinical Activity, and Pharmacokinetics of Al flutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2020, 卷号: 15, 期号: 6, 页码: 1015-1026
作者:  Shi, Yuankai;  Zhang, Shucai;  Hu, Xingsheng;  Feng, Jifeng;  Ma, Zhiyong
收藏  |  浏览/下载：38/0  |  提交时间：2020/12/24
Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance 期刊论文
MOLECULAR CANCER, 2020, 卷号: 19, 期号: 1, 页码: 15
作者:  Zhang, Tao;  Qu, Rong;  Chan, Shingpan;  Lai, Mengzhen;  Tong, Linjiang
收藏  |  浏览/下载：40/0  |  提交时间：2020/07/01

©版权所有 ©2017 CSpace - Powered by CSpace